KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Net Cash Flow (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Net Cash Flow for 8 consecutive years, with $75.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 171275.0% year-over-year to $75.4 million, compared with a TTM value of $23.1 million through Dec 2025, down 63.06%, and an annual FY2025 reading of $23.1 million, down 63.06% over the prior year.
  • Net Cash Flow was $75.4 million for Q4 2025 at Esperion Therapeutics, up from $6.4 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $144.4 million in Q1 2024 and bottomed at -$87.0 million in Q1 2021.
  • Average Net Cash Flow over 5 years is -$6.9 million, with a median of -$25.5 million recorded in 2022.
  • The sharpest move saw Net Cash Flow tumbled 2299.2% in 2022, then skyrocketed 171275.0% in 2025.
  • Year by year, Net Cash Flow stood at $105.2 million in 2021, then tumbled by 180.43% to -$84.6 million in 2022, then soared by 61.49% to -$32.6 million in 2023, then soared by 100.14% to $44000.0 in 2024, then surged by 171275.0% to $75.4 million in 2025.
  • Business Quant data shows Net Cash Flow for ESPR at $75.4 million in Q4 2025, $6.4 million in Q3 2025, and -$28.6 million in Q2 2025.